Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Schrödinger, Inc. (Nasdaq: SDGR) announced new preclinical data on its small-molecule MALT1 inhibitors, to be presented at the American Society of Hematology's Annual Meeting from December 11-14, 2021, in Atlanta, Georgia. MALT1 inhibitors are a promising therapeutic route for certain non-Hodgkin B-cell lymphomas and chronic lymphocytic leukemia (CLL). The lead MALT1 inhibitor is expected to enter clinical trials next year. The presentation will cover characterization details, which may enhance investor interest and highlight the company's innovative drug discovery approach.
Schrödinger (Nasdaq: SDGR) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results. The call will provide an update on the company's business and can be accessed via its website's investor section. Schrödinger specializes in a physics-based software platform aimed at revolutionizing therapeutic and material discovery, offering faster and cost-effective solutions for its clients in multiple sectors.
Schrödinger (Nasdaq:SDGR) and Centessa Pharmaceuticals (Nasdaq:CNTA) announced an exclusive collaboration to discover novel therapeutics targeting the orexin-2 receptor (OX2R), relevant for sleep disorders like narcolepsy. This partnership marks the first large-scale application of Schrödinger's computational platform in orexin agonist development, leveraging Orexia’s structural biology capabilities. Orexia will manage preclinical research and commercialization, while Schrödinger will receive upfront payments and potential royalties on global sales. The collaboration aims to explore orexin agonists for various disorders characterized by excessive daytime sleepiness.
Schrödinger, Inc. (Nasdaq: SDGR) announced on
Schrödinger, Inc. (Nasdaq: SDGR) has announced a strategic two-year collaboration with The University of Texas MD Anderson Cancer Center to advance its WEE1 inhibitor program. The partnership aims to optimize therapeutic development through biomarker-driven patient stratification and clinical study prioritization. Schrödinger's WEE1 inhibitors showed promising preclinical results, and the collaboration will investigate their potential as single agents and in combination therapies for specific cancer types. Schrödinger retains sole responsibility for development and commercialization of these compounds.
Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options for 45,050 shares to 15 newly hired employees on
Schrödinger (Nasdaq: SDGR) has announced its participation in four investor conferences in September 2021. On September 9 at 2:00 p.m. ET, the company will present at the Morgan Stanley 19th Annual Global Healthcare Conference. A pre-recorded presentation will be available on September 13. Additionally, Schrödinger will participate in the BofA Global Healthcare Conference on September 16 and the BofA Securities Drug Discovery Conference on September 20. Live webcasts can be accessed on their website and will be archived for about seven days.
Schrödinger, Inc. (Nasdaq: SDGR) recently granted stock options to 13 new employees, totaling 25,150 shares under its 2021 Inducement Equity Incentive Plan. The options, priced at $57.40 per share, were approved by the compensation committee and are intended to attract talent. Each option has a 10-year term, vesting over four years. Schrödinger's innovative software platform advances drug development and material science, serving clients globally to accelerate the discovery of novel therapeutics.
Schrödinger (Nasdaq: SDGR) announced a 29% increase in Q2 2021 revenue to $29.8 million, with software revenue rising 15% to $24.1 million. The company reported a gross profit of $12 million, though overall operating expenses grew to $42.3 million, leading to a net loss of $34.6 million. Notably, Schrödinger has partnered with Zai Lab to co-develop an oncology program, and expects to submit up to three IND applications in 2022. The company anticipates full-year revenue between $124 million and $142 million. Cash and equivalents totaled $616.6 million as of June 30, 2021.
Schrödinger (Nasdaq: SDGR) and Zai Lab (Nasdaq: ZLAB; HKEX: 9688) have announced a collaboration to jointly discover, develop, and commercialize a novel oncology program targeting DNA damage response. Zai Lab will initially fund Schrödinger's research costs and lead global development post candidate selection. Schrödinger retains co-development rights in the U.S. and can earn up to $338 million in milestone payments, plus royalties on international sales. This partnership aims to leverage both companies' expertise to accelerate innovative cancer therapies.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
